ARNA Volume Alert - ARNA 4.33 Arena Pharmaceutical

ARNA Volume Alert - ARNA 4.33 Arena Pharmaceuticals $ARNA Hit a high of 4.38 Currently 11:15 Last price 4.33 +0.07 +1.64% With a day low of 4.22 and a current volume of 1,814,776.

ARNA Arena Pharmaceuticals Recent Headline News

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 20 mins ago

OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.23 (-0.10), AMAG: 34.75 (-0.20), ARNA: 4.34 (+0.08)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.11 (+1.26), ARNA: 4.34 (+0.08)

Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST

ARNA: 4.34 (+0.08)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.29 (+0.84), CLVS: 59.13 (+0.82), ARWR: 6.24 (+0.18), ACHN: 12.56 (+2.45), MRK: 58.80 (-0.54), RTRX: 10.52 (+0.14), RGLS: 21.41 (-0.67), EPZM: 23.61 (-0.14), AGIO: 79.67 (+7.61), RMTI: 10.60 (+0.05), ARNA: 4.34 (+0.08), KERX: 16.38 (-0.35)

Arena product revenues up 185%
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:36AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:56AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.34 (+0.08)

Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
PR Newswire - Mon Nov 03, 5:30AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.
ARNA: 4.34 (+0.08)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.90 (-0.05), SYY: 38.49 (+0.35), L: 43.26 (-0.25), EEP: 35.72 (-0.21), SNH: 22.34 (+0.06), INN: 11.67 (unch), ITG: 19.68 (-0.11), NSP: 33.53 (-0.41), S: 4.86 (+0.14), ALE: 52.35 (+0.10), GVA: 36.30 (-0.06), MCY: 55.28 (+0.35), ARNA: 4.34 (+0.08), CHD: 73.45 (+0.18), ARE: 83.70 (+1.32), USAK: 17.45 (-0.02), BWP: 17.05 (+0.03), KRG: 26.80 (+0.04), CYOU: 23.58 (+1.17), MNKD: 5.86 (+0.08), HNT: 47.49 (+0.48), AMH: 17.26 (+0.16), ARCB: 42.59 (+0.19), ANIP: 49.42 (+3.42), AMG: 195.24 (-1.46), HAE: 36.54 (-0.28), SOHU: 51.00 (+0.66), CNA: 39.31 (+0.24)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 4:39PM CDT

FRM: 6.32 (+0.16), TTMI: 6.82 (-0.10), EGO: 5.30 (-0.34), AMBR: 11.17 (-0.23), BDBD: 9.04 (+0.28), DUST: 39.94 (+6.03), BZH: 19.18 (+0.62), ARNA: 4.34 (+0.08), GSAT: 2.64 (+0.02), CTCT: 35.28 (+0.24)